Sign In
Buy REGN
$618.95
+16.03 (+2.66%)
At Close: Jun 03, 2026
Regeneron Pharmaceuticals Q3 tops earnings and revenue marks
06:51am, Thursday, 03'rd Nov 2022
Regeneron Pharmaceuticals Inc. REGN, -2.56% said Thursday its third-quarter net income fell 19% to $1.32 billion or $11.66 a share, from $1.63 billion or $14.33 a share, in the year-ago period. Adjust
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022
02:27pm, Tuesday, 01'st Nov 2022 Benzinga
Upgrades
For AnaptysBio Inc (NASDAQ:ANAB), Guggenheim upgraded the previous rating of Neutral to Buy. AnaptysBio earned $1.15 in the second quarter, compared to $0.02 in the year-ago quarter. The sto
Top Stock Reports for Exxon Mobil, T-Mobile US & Intuitive Surgical
07:43pm, Monday, 31'st Oct 2022 Zacks Investment Research
Today's Research Daily features new research reports on 16 major stocks, including Exxon Mobil Corporation (XOM), T-Mobile US, Inc. (TMUS) and Intuitive Surgical, Inc. (ISRG).
Regeneron (REGN) Q3 Earnings Coming Up: What's in the Cards?
03:49pm, Monday, 31'st Oct 2022 Zacks Investment Research
Regeneron's (REGN) third-quarter earnings are likely to have got a boost from the solid performance of Eylea and Dupixent.
Should Invesco S&P 500 GARP ETF (SPGP) Be on Your Investing Radar?
10:20am, Monday, 31'st Oct 2022 Zacks Investment Research
Style Box ETF report for SPGP
Sanofi (SNY) Q3 Earnings Beat, Dupixent, Flu Jabs Push Sales
04:51pm, Friday, 28'th Oct 2022 Zacks Investment Research
Sanofi (SNY) beats third-quarter estimates for earnings and sales. Dupixent and flu vaccines drive sales growth. The company raises its earnings growth guidance for 2022.
Final Trades: Boeing, Amazon, Regeneron & more
02:18pm, Friday, 28'th Oct 2022
The "Halftime Report" traders give their top picks to watch for the second half.
Why Regeneron (REGN) Could Beat Earnings Estimates Again
04:10pm, Thursday, 27'th Oct 2022 Zacks Investment Research
Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Alnylam's (ALNY) Earnings and Revenues Lag Estimates in Q3
03:00pm, Thursday, 27'th Oct 2022 Zacks Investment Research
Alnylam's (ALNY) earnings and sales fall shy of estimates in the third quarter of 2022. The company maintains its product revenue guidance for 2022.
Regeneron (REGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
02:02pm, Thursday, 27'th Oct 2022 Zacks Investment Research
Regeneron (REGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biotech Stock Roundup: BIIB & BMY's Q3 Earnings, TCDA Down on Study Update
04:07pm, Wednesday, 26'th Oct 2022 Zacks Investment Research
Earnings updates from BIIB and BMY are the key highlights from the biotech sector during the past week.
Benzinga's Top Ratings Upgrades, Downgrades For October 26, 2022
02:07pm, Wednesday, 26'th Oct 2022 Benzinga
Upgrades
For Enterprise Financial Services Corp (NASDAQ:EFSC), DA Davidson upgraded the previous rating of Neutral to Buy. For the third quarter, Enterprise Finl Servs had an EPS of $1.32, compared to
Regeneron (REGN) Gains But Lags Market: What You Should Know
10:15pm, Tuesday, 25'th Oct 2022 Zacks Investment Research
In the latest trading session, Regeneron (REGN) closed at $747.33, marking a +1.38% move from the previous day.
Sanofi (SNY) to Report Q3 Earnings: What's in the Cards?
02:53pm, Tuesday, 25'th Oct 2022 Zacks Investment Research
Sanofi's (SNY) top line is likely to have been driven by higher sales of Dupixent and vaccines.
Biosimilars Are Revolutionizing Healthcare: Is This Industry Leader a Buy?
10:50am, Tuesday, 25'th Oct 2022 The Motley Fool
Biosimilars are bringing down prescription drug costs without sacrificing quality.
